Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACULAR vs FASTIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.
Sympathomimetic amine that promotes release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, suppressing appetite.
Treatment of postoperative inflammation in patients who have undergone cataract extraction,Relief of ocular itching due to seasonal allergic conjunctivitis
Short-term adjunct in exogenous obesity,Off-label: Attention deficit hyperactivity disorder (ADHD)
One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.
30 mg orally once daily in the morning, administered as a single dose.
Terminal half-life: 1.8 hours (ketorolac tromethamine); clinical context: short half-life supports dosing every 6 hours for acute pain, but prolonged in elderly or renal impairment (↑ to 5-6 hours, thus dose reduction required).
Terminal elimination half-life is approximately 16-20 hours for the immediate-release formulation. With sustained-release forms, effective half-life may extend to 24-34 hours due to prolonged absorption. Clinical context: time to reach steady state is about 3-5 days.
Hepatic metabolism primarily via cytochrome P450 2C9 (CYP2C9).
Hepatic metabolism via CYP3A4 and CYP2D6; active metabolite phendimetrazine (for some formulations).
Renal: ~80% as unchanged drug and glucuronide conjugates; biliary/fecal: ~20%
Primarily renal (approximately 70-80% unchanged) and biliary/fecal (20-30% as metabolites). Urinary excretion is p H-dependent; acidic urine increases elimination.
99% bound; primary binding protein: albumin.
Approximately 40-50% bound to plasma proteins (albumin).
0.11-0.25 L/kg; clinical meaning: low Vd indicates primarily confined to extracellular compartment (plasma and interstitial fluid), minimal tissue penetration.
Approximately 3-5 L/kg. High Vd indicates extensive tissue distribution, including brain.
Ophthalmic: ~2% systemic absorption after topical instillation (due to corneal permeability and nasolacrimal drainage); oral formulation not used for Acular (ophthalmic only).
Oral immediate-release: ~90% (high first-pass metabolism; absolute bioavailability is lower, but systemic exposure is adequate). Oral sustained-release: similar extent but with prolonged absorption.
No dosage adjustment required for renal impairment.
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73 m²). For moderate impairment (e GFR 30-59 m L/min/1.73 m²), reduce dose to 15 mg once daily.
No dosage adjustment required for hepatic impairment.
Contraindicated in Child-Pugh class C cirrhosis. In Child-Pugh class A or B, initiate at 15 mg once daily and titrate cautiously to maximum 30 mg once daily.
Safety and efficacy in pediatric patients have not been established; use not recommended.
Not recommended for pediatric patients under 16 years of age due to lack of safety and efficacy data.
No specific dosage adjustment required; use same dosing as for younger adults.
Initiating at 15 mg once daily is recommended due to increased sensitivity and potential for central nervous system adverse effects; maximum dose 30 mg once daily.
No FDA boxed warning.
None.
May increase bleeding time due to inhibition of platelet aggregation; use with caution in patients with known bleeding tendencies or those receiving other medications that may prolong bleeding time.,May cause corneal effects including keratitis and corneal thinning; discontinue if corneal epithelial breakdown occurs.,Use with caution in patients with prior sensitivity to aspirin, phenylacetic acid derivatives, or other NSAIDs.,May delay wound healing or exacerbate infections; avoid use in patients with active epithelial herpes simplex keratitis.
Cardiovascular events (hypertension, tachycardia, stroke), psychiatric adverse effects (psychosis, dependence), primary pulmonary hypertension, valvular heart disease, tolerance, withdrawal symptoms, glaucoma, hyperthyroidism, seizure disorder, diabetes (dose adjustment required), elderly patients (higher sensitivity).
Hypersensitivity to ketorolac tromethamine or any component of the formulation,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Active epithelial herpes simplex keratitis,Late pregnancy (third trimester) due to risk of premature closure of ductus arteriosus
Cardiovascular disease (e.g., coronary artery disease, arrhythmias, hypertension), hyperthyroidism, glaucoma, agitated states, history of drug abuse, MAOIs (concurrent or within 14 days), hypersensitivity to sympathomimetics.
No known food interactions. Avoid alcohol if concomitant oral NSAIDs are used due to increased risk of gastrointestinal bleeding, but this is not specific to ophthalmic use.
Avoid excessive caffeine intake (e.g., coffee, tea, cola, energy drinks) as it may potentiate CNS and cardiovascular effects. Grapefruit juice may alter drug metabolism; avoid concurrent consumption. Maintain a balanced, reduced-calorie diet as part of the weight loss plan. Alcohol should be avoided due to potential additive CNS effects.
Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairment in the third trimester. First and second trimester use should be avoided unless clearly needed. The potential benefits should be weighed against the risks.
FDA Pregnancy Category X. First trimester: Increased risk of oral clefts and cardiac malformations with amphetamine use. Second and third trimesters: Risk of premature delivery, low birth weight, and neonatal withdrawal syndrome. Avoid use in pregnancy.
Ketorolac is excreted in human milk at low levels. The M/P ratio is not well defined. Due to potential adverse effects in nursing infants, caution is advised. Use only if clearly indicated and consider alternative agents.
Excreted in human milk; M/P ratio not established. Potential for adverse effects in nursing infants (irritability, poor feeding). Contraindicated during breastfeeding.
No specific dose adjustments are recommended for pregnancy; however, use the lowest effective dose for the shortest duration due to potential fetal risks. Physiological changes in pregnancy (increased volume of distribution, renal clearance) may alter pharmacokinetics, but no formal studies justify dose modification.
Contraindicated in pregnancy; no dose adjustments recommended.
ACULAR (ketorolac tromethamine ophthalmic solution) is a nonsteroidal anti-inflammatory drug (NSAID) used for ocular inflammation. Avoid concomitant use with other NSAIDs or corticosteroids due to increased risk of corneal adverse events. Use with caution in patients with bleeding disorders or those on anticoagulants, as it may increase bleeding tendency. Monitor for corneal toxicity, especially in patients with compromised corneal integrity. Ensure proper storage at room temperature and discard if solution changes color or becomes cloudy.
Fastin (phentermine) is a sympathomimetic amine indicated for short-term (up to 12 weeks) monotherapy for obesity. It should be used in conjunction with a reduced-calorie diet and exercise. Avoid co-administration with MAOIs or within 14 days of MAOI use due to hypertensive crisis risk. Use with caution in patients with hypertension, diabetes, or history of drug abuse. Monitor blood pressure and heart rate regularly. Tachyphylaxis may develop; discontinue if tolerance occurs. Do not use in patients with advanced arteriosclerosis, hyperthyroidism, glaucoma, or agitated states.
Do not touch the dropper tip to any surface to avoid contamination.,Remove contact lenses before instillation and wait at least 15 minutes before reinserting.,Apply pressure to the inner corner of the eye (nasolacrimal occlusion) for 1 minute after instillation to reduce systemic absorption.,Do not use while wearing soft contact lenses, as the preservative may be absorbed.,Report any signs of corneal problems such as pain, redness, or vision changes immediately.,Use exactly as prescribed and do not share the medication with others.
Take Fastin exactly as prescribed, usually once daily in the morning to avoid insomnia.,Do not crush or chew the extended-release capsule; swallow whole.,Avoid taking late in the day to prevent difficulty sleeping.,Report any chest pain, palpitations, shortness of breath, or dizziness immediately.,Do not increase dose or take more frequently than prescribed; risk of dependence and side effects.,Fastin is for short-term use only (up to 12 weeks) and should be combined with a reduced-calorie diet and exercise.,Do not use if you have taken an MAO inhibitor in the last 14 days.,Avoid alcohol and other CNS stimulants (e.g., caffeine in large amounts) as they may increase side effects.,Do not stop abruptly; follow your doctor's instructions for tapering off.,Keep out of reach of children; misuse can cause severe cardiac toxicity.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACULAR vs FASTIN, answered by our medical review team.
ACULAR is a NSAID Ophthalmic that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which decreases inflammation, pain, and fever.. FASTIN is a Sympathomimetic Anorectic that works by Sympathomimetic amine that promotes release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, suppressing appetite.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACULAR and FASTIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACULAR is: One drop of 0.5% ophthalmic solution into the affected eye(s) four times daily.. The standard adult dose of FASTIN is: 30 mg orally once daily in the morning, administered as a single dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACULAR and FASTIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACULAR is classified as Category C. Pregnancy Category C. No adequate studies in pregnant women. Ketorolac tromethamine, like other NSAIDs, may cause premature closure of the ductus arteriosus and fetal renal impairm. FASTIN is classified as Category C. FDA Pregnancy Category X. First trimester: Increased risk of oral clefts and cardiac malformations with amphetamine use. Second and third trimesters: Risk of premature delivery, lo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.